Last --
Change Today 0.00 / 0.00%
Volume 0.0
2370 On Other Exchanges
Symbol
Exchange
2370 is not on other exchanges.
All times are local (Market data is delayed by at least 15 minutes).

medinet co ltd (2370) Snapshot

Open
--
Previous Close
--
Day High
--
Day Low
--
52 Week High
-- - --
52 Week Low
-- - --
Market Cap
--
Average Volume 10 Days
0.0
EPS TTM
--
Shares Outstanding
0.0
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for MEDINET CO LTD (2370)

Related News

No related news articles were found.

medinet co ltd (2370) Related Businessweek News

No Related Businessweek News Found

medinet co ltd (2370) Details

MEDINET Co., Ltd. provides immuno-cell therapy total support services to medical institutions for conducting cancer immuno-cell therapy in Japan. The company’s immuno-cell therapy total support services include the provision of design, layout, installation, and operation management of cell processing facilities; biotechnology for cell culture and processing, and know-how for quality control; cell engineers for cell processing and quality check; materials, reagents, and consumables supply services; and custom-made medical practice management system. Its technology pipeline comprises dendritic cell vaccine therapy, natural killer-cell therapy, gamma-delta T-cell therapy, alpha-beta T-cell therapy, and cytotoxic T-lymphocyte therapy. The company was founded in 1995 and is headquartered in Yokohama, Japan.

158 Employees
Last Reported Date: 12/19/13
Founded in 1995

medinet co ltd (2370) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

medinet co ltd (2370) Key Developments

Medinet Appoints Kunihiko Suzuki as Director, Effective from October 01, 2014

Medinet will appoint Kunihiko Suzuki as a Director. The effective date is October 01, 2014.

MEDINET Co., Ltd. Announces Consolidated Financial Results for the Nine Months Ended June 2014; Provides Earnings Guidance for the Year Ending September 30, 2014

MEDINET Co., Ltd. announced consolidated financial results for the nine months ended June 2014. For the period, the company reported net sales of ¥1,417 million against ¥1,561 million a year ago. Operating loss was ¥1,008 million against ¥659 million a year ago. Ordinary loss of ¥1,041 million or ¥731 million a year ago. Net loss was ¥635 million or ¥7.23 per share against ¥121 million or ¥1.55 per share a year ago. Loss before income taxes was ¥629.614 million against ¥121.281 million a year ago. Loss before minority interest was ¥635.931 million against ¥121.633 million a year ago. For the year ending September 30, 2014 the company expects net sales of ¥1.8 billion, operating loss of ¥1.430 billion, ordinary loss of ¥1.460 billion, net loss of ¥1.060 billion or ¥12.03 per share.

MEDINET Co., Ltd. to Report Q3, 2014 Results on Aug 05, 2014

MEDINET Co., Ltd. announced that they will report Q3, 2014 results at 3:00 PM, Tokyo Standard Time on Aug 05, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
2370:JP ¥238.00 JPY -5.00

2370 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 2370.
View Industry Companies
 

Industry Analysis

2370

Industry Average

Valuation 2370 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 30.9x
Price/Book 6.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 6.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MEDINET CO LTD, please visit www.medinet-inc.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.